Pelanserin (developmental code name TR-2515) is a serotonin 5-HT<sub>2</sub> and ñ<sub>1</sub>-adrenergic receptor antagonist which was under development for the treatment of hypertension but was never marketed. Its development was discontinued in 2001.
The pharmacokinetics of pelanserin have been studied. It has a relatively short elimination half-life. The drug's time to peak levels was less than 1hour and its half-life was 3.8hours in a single subject in an analytical study.
Pelanserin (3) can be synthesized by a reaction between isatoic anhydride (1) and 1-(3-aminopropyl)-4-phenylpiperazine (2) in the presence of phosgene.